04 December 2019 | News
Dr. Reddy’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only
Dr. Reddy’s Laboratories has announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by USFDA via a 505(b)(2) new drug application (NDA) pathway for intravenous use only.
Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories said, “We’re pleased to bring this product to market for the customers and patients who will benefit from this cost efficient alternative in the market place. This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio of products in the Hospital segment.”
Dr. Reddy’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.